A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway

Clinical trial NCT06614751 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06614751
Sponsor: Danatlas Pharmaceuticals Co., Ltd
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Cancers BRCA Mutation HRD Cancer Breast Cancer Prostate Cancer Colorectal Cancer Pancreatic Cancer Endometrial Cancer Gastric Cancer Advanced Cancer Metastatic Solid Tumors

Start date: 2024-11-01
Primary completion: 2026-11-01
Enrollment: 112

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.